Envoy Medical Signs Material Definitive Agreement

TL;DR

Envoy Medical signed a big deal on Dec 19th, filing shows.

AI Summary

Envoy Medical, Inc. entered into a Material Definitive Agreement on December 19, 2024. The filing also includes financial statements and exhibits related to this agreement. The company was formerly known as Anzu Special Acquisition Corp I until January 15, 2021.

Why It Matters

This filing indicates a significant new contract or partnership for Envoy Medical, which could impact its future financial performance and strategic direction.

Risk Assessment

Risk Level: medium — Material definitive agreements can introduce new risks or opportunities, and the specifics of this agreement are not detailed in the provided excerpt.

Key Players & Entities

• Envoy Medical, Inc. (company) — Registrant
• Anzu Special Acquisition Corp I (company) — Former company name
• December 19, 2024 (date) — Date of earliest event reported
• January 15, 2021 (date) — Date of name change

FAQ

Key Financial Figures

• $0.0001 — tered Class A Common Stock, par value $0.0001 per share COCH The Nasdaq Stock Mar
• $11.50 — A Common Stock at an exercise price of $11.50 per share COCHW The Nasdaq Stock Ma
• $10.46 — Common Stock ") at an exercise price of $10.46 per share. On November 27, 2023, the Co

Filing Documents

• ea0225757-8k_envoy.htm (8-K) — 30KB
• ea022575701ex10-1_envoy.htm (EX-10.1) — 12KB
• 0001213900-24-111932.txt ( ) — 261KB
• coch-20241219.xsd (EX-101.SCH) — 4KB
• coch-20241219_def.xml (EX-101.DEF) — 26KB
• coch-20241219_lab.xml (EX-101.LAB) — 36KB
• coch-20241219_pre.xml (EX-101.PRE) — 25KB
• ea0225757-8k_envoy_htm.xml (XML) — 6KB

01: Entry Into a Material Definitive Agreement

Item 1.01: Entry Into a Material Definitive Agreement As previously disclosed, on April 17, 2023, Envoy Medical, Inc. (formerly known as Anzu Special Acquisition Corp I) (the " Company ") and Envoy Medical Corporation (" Legacy Envoy ") entered into an agreement (as amended to date, the " Forward Purchase Agreement ") with Meteora Special Opportunity Fund I, LP (" MSOF "), Meteora Capital Partners, LP (" MCP "), Meteora Select Trading Opportunities Master, LP (" MSTO ") and Meteora Strategic Capital, LLC (" MSC " and, collectively with MSOF, MCP and MSTO, the " Meteora FPA Parties ") for an OTC Equity Prepaid Forward Transaction. Pursuant to the terms of the Forward Purchase Agreement, among other things, the Company issued 3,874,394 warrants (the " Shortfall Warrants ") to purchase up to 3,874,394 shares (the " Shortfall Warrant Shares ") of the Company's Class A common stock, par value $0.0001 per share (the " Common Stock ") at an exercise price of $10.46 per share. On November 27, 2023, the Company and the Meteora FPA Parties entered into a Common Stock Purchase Warrant (the " Common Stock Purchase Warrant "), pursuant to which the Company issued to the Meteora FPA Parties Shortfall Warrants to purchase up to 3,874,394 shares of Common Stock. Also as previously reported, on June 24, 2024, the Company and the Meteora FPA Parties entered into Amendment No. 1 to the Common Stock Purchase Warrant (the " First Shortfall Warrant Amendment "). The First Shortfall Warrant Amendment provided for the extension of the expiration date of the Shortfall Warrants by six months, from June 30, 2024 to December 31, 2024. On December 19, 2024, the Company and the Meteora FPA Parties entered into Amendment No. 2 to the Common Stock Purchase Warrant (the " Second Shortfall Warrant Amendment "). The Second Shortfall Warrant Amendment provided for the further extension of the expiration date of the Shortfall Warrants by 12 months, from December 31, 2024 to December 31, 2025. The

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ENVOY MEDICAL, INC. December 23, 2024 By: /s/ David R. Wells David R. Wells Chief Financial Officer 2

View Full Filing

View this 8-K filing on SEC EDGAR